疫苗平台和卡介苗接种对 COVID-19 疫苗接种抗体反应的影响。
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.
机构信息
Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
出版信息
Front Immunol. 2023 Jul 3;14:1172851. doi: 10.3389/fimmu.2023.1172851. eCollection 2023.
Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.
多种因素，包括疫苗平台和既往疫苗接种，影响疫苗反应。我们比较了巴西 874 名医护人员接种科兴（Sinovac）和腺病毒载体疫苗（AstraZeneca-Oxford）的抗体反应。由于参与者作为 BCG 疫苗接种减少 COVID-19 对医护人员影响（BRACE）试验的一部分，在前 0-6 个月随机接受 BCG 疫苗或安慰剂接种，我们还研究了最近 BCG 疫苗接种对这些 COVID-19 疫苗抗体反应的影响。两种疫苗第二剂接种后 28 天，腺病毒载体疫苗诱导的抗刺突 IgG 反应强于科兴疫苗。最近的 BCG 疫苗接种不影响腺病毒载体疫苗或科兴疫苗的 IgG 抗体反应。
Zotero 插件